Diagnostic Performance of Whole-Body PET/MRI for Detecting Malignancies in Cancer Patients: A Meta-Analysis

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2016 Apr 29

PMID 27124545

Citations 6

Authors

Guohua Shen

Shuang Hu

Bin Liu

Anren Kuang

Affiliations

Soon will be listed here.

Abstract

Background: As an evolving imaging modality, PET/MRI is preliminarily applied in clinical practice. The aim of this study was to assess the diagnostic performance of PET/MRI for tumor staging in patients with various types of cancer.

Methods: Relevant articles about PET/MRI for cancer staging were systematically searched in PubMed, EMBASE, EBSCO and the Cochrane Library. Two researchers independently selected studies, extracted data and assessed the methodological quality using the QUADAS tool. The pooled sensitivity, specificity, diagnostic odds ratio (DOR), positive likelihood ratio (PLR), and negative likelihood ratio (NLR) were calculated per patient and per lesion. The summary receiver-operating characteristic (SROC) curves were also constructed, and the area under the curve (AUC) and Q* estimates were obtained.

Results: A total of 38 studies that involved 753 patients and 4234 lesions met the inclusion criteria. On a per-patient level, the pooled sensitivity and specificity with 95% confidence intervals (CIs) were 0.93 (0.90-0.95) and 0.92 (0.89-0.95), respectively. On a per-lesion level, the corresponding estimates were 0.90 (0.88-0.92) and 0.95 (0.94-0.96), respectively. The pooled PLR, NLR and DOR estimates were 6.67 (4.83-9.19), 0.12 (0.07-0.21) and 75.08 (42.10-133.91) per patient and 10.91 (6.79-17.54), 0.13 (0.08-0.19) and 102.53 (59.74-175.97) per lesion, respectively.

Conclusion: According to our results, PET/MRI has excellent diagnostic potential for the overall detection of malignancies in cancer patients. Large, multicenter and prospective studies with standard scanning protocols are required to evaluate the diagnostic value of PET/MRI for individual cancer types.

Citing Articles

MRI compatibility study of a prototype radiofrequency penetrable oval PET insert at 3 T.

Akram M, Nishikido F, Levin C, Takyu S, Obata T, Yamaya T Jpn J Radiol. 2023; 42(4):382-390.

PMID: 38110835 DOI: 10.1007/s11604-023-01514-y.

Study on the radiofrequency transparency of partial-ring oval-shaped prototype PET inserts in a 3 T clinical MRI system.

Akram M, Levin C, Nishikido F, Takyu S, Obata T, Yamaya T Radiol Phys Technol. 2023; 17(1):60-70.

PMID: 37874462 DOI: 10.1007/s12194-023-00747-w.

Diagnostic performance of whole-body [F]FDG PET/MR in cancer M staging: A systematic review and meta-analysis.

Mirshahvalad S, Kohan A, Metser U, Hinzpeter R, Ortega C, Farag A Eur Radiol. 2023; 34(1):673-685.

PMID: 37535156 DOI: 10.1007/s00330-023-10009-3.

Primary large cell prostate neuroendocrine carcinoma with central and nephrogenic diabetes insipidus.

Basatac C, Saglam S, Aktepe F, Akpinar H Int Braz J Urol. 2020; 46(5):859-863.

PMID: 32648432 PMC: 7822364. DOI: 10.1590/S1677-5538.IBJU.2019.0180.

Microstrip Transmission Line RF Coil for a PET/MRI Insert.

Akram M, Obata T, Yamaya T Magn Reson Med Sci. 2019; 19(2):147-153.

PMID: 31776297 PMC: 7232037. DOI: 10.2463/mrms.mp.2019-0137.

References

Brendle C, Schwenzer N, Rempp H, Schmidt H, Pfannenberg C, Fougere C . Assessment of metastatic colorectal cancer with hybrid imaging: comparison of reading performance using different combinations of anatomical and functional imaging techniques in PET/MRI and PET/CT in a short case series. Eur J Nucl Med Mol Imaging. 2015; 43(1):123-132. DOI: 10.1007/s00259-015-3137-z. View

Pfluger T, Melzer H, Mueller W, Coppenrath E, Bartenstein P, Albert M . Diagnostic value of combined ¹⁸F-FDG PET/MRI for staging and restaging in paediatric oncology. Eur J Nucl Med Mol Imaging. 2012; 39(11):1745-55. DOI: 10.1007/s00259-012-2228-3. View

Flechsig P, Mehndiratta A, Haberkorn U, Kratochwil C, Giesel F . PET/MRI and PET/CT in Lung Lesions and Thoracic Malignancies. Semin Nucl Med. 2015; 45(4):268-81. DOI: 10.1053/j.semnuclmed.2015.03.004. View

Higgins J, Thompson S . Quantifying heterogeneity in a meta-analysis. Stat Med. 2002; 21(11):1539-58. DOI: 10.1002/sim.1186. View

Kohan A, Kolthammer J, Vercher-Conejero J, Rubbert C, Partovi S, Jones R . N staging of lung cancer patients with PET/MRI using a three-segment model attenuation correction algorithm: initial experience. Eur Radiol. 2013; 23(11):3161-9. DOI: 10.1007/s00330-013-2914-y. View

Queiroz M, Hullner M, Kuhn F, Huber G, Meerwein C, Kollias S . Use of diffusion-weighted imaging (DWI) in PET/MRI for head and neck cancer evaluation. Eur J Nucl Med Mol Imaging. 2014; 41(12):2212-21. DOI: 10.1007/s00259-014-2867-7. View

Antoch G, Vogt F, Freudenberg L, Nazaradeh F, Goehde S, Barkhausen J . Whole-body dual-modality PET/CT and whole-body MRI for tumor staging in oncology. JAMA. 2003; 290(24):3199-206. DOI: 10.1001/jama.290.24.3199. View

Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Takahashi S . Value of fusion of PET and MRI for staging of endometrial cancer: comparison with ¹⁸F-FDG contrast-enhanced PET/CT and dynamic contrast-enhanced pelvic MRI. Eur J Radiol. 2013; 82(10):1672-6. DOI: 10.1016/j.ejrad.2013.05.005. View

Mawlawi O, Townsend D . Multimodality imaging: an update on PET/CT technology. Eur J Nucl Med Mol Imaging. 2008; 36 Suppl 1:S15-29. DOI: 10.1007/s00259-008-1016-6. View

10.

Gatidis S, Schmidt H, Gucke B, Bezrukov I, Seitz G, Ebinger M . Comprehensive Oncologic Imaging in Infants and Preschool Children With Substantially Reduced Radiation Exposure Using Combined Simultaneous ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography/Magnetic Resonance Imaging: A Direct Comparison to.... Invest Radiol. 2015; 51(1):7-14. DOI: 10.1097/RLI.0000000000000200. View

11.

Paspulati R, Partovi S, Herrmann K, Krishnamurthi S, Delaney C, Nguyen N . Comparison of hybrid FDG PET/MRI compared with PET/CT in colorectal cancer staging and restaging: a pilot study. Abdom Imaging. 2015; 40(6):1415-25. DOI: 10.1007/s00261-015-0474-0. View

12.

Nagamachi S, Nishii R, Wakamatsu H, Mizutani Y, Kiyohara S, Fujita S . The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT. Ann Nucl Med. 2013; 27(6):554-63. DOI: 10.1007/s12149-013-0719-3. View

13.

Platzek I, Beuthien-Baumann B, Schneider M, Gudziol V, Kitzler H, Maus J . FDG PET/MR for lymph node staging in head and neck cancer. Eur J Radiol. 2014; 83(7):1163-1168. DOI: 10.1016/j.ejrad.2014.03.023. View

14.

Judenhofer M, Cherry S . Applications for preclinical PET/MRI. Semin Nucl Med. 2012; 43(1):19-29. DOI: 10.1053/j.semnuclmed.2012.08.004. View

15.

Beiderwellen K, Geraldo L, Ruhlmann V, Heusch P, Gomez B, Nensa F . Accuracy of [18F]FDG PET/MRI for the Detection of Liver Metastases. PLoS One. 2015; 10(9):e0137285. PMC: 4559465. DOI: 10.1371/journal.pone.0137285. View

16.

Vandecaveye V, De Keyzer F, Vander Poorten V, Dirix P, Verbeken E, Nuyts S . Head and neck squamous cell carcinoma: value of diffusion-weighted MR imaging for nodal staging. Radiology. 2009; 251(1):134-46. DOI: 10.1148/radiol.2511080128. View

17.

Xu G, Zhao L, He Z . Performance of whole-body PET/CT for the detection of distant malignancies in various cancers: a systematic review and meta-analysis. J Nucl Med. 2012; 53(12):1847-54. DOI: 10.2967/jnumed.112.105049. View

18.

Kitajima K, Suenaga Y, Ueno Y, Kanda T, Maeda T, Deguchi M . Fusion of PET and MRI for staging of uterine cervical cancer: comparison with contrast-enhanced (18)F-FDG PET/CT and pelvic MRI. Clin Imaging. 2014; 38(4):464-469. DOI: 10.1016/j.clinimag.2014.02.006. View

19.

Bitencourt A, Lima E, Chojniak R, Marques E, Souza J, Andrade W . Multiparametric evaluation of breast lesions using PET-MRI: initial results and future perspectives. Medicine (Baltimore). 2014; 93(22):e115. PMC: 4616313. DOI: 10.1097/MD.0000000000000115. View

20.

Loeffelbein D, Souvatzoglou M, Wankerl V, Dinges J, Ritschl L, Mucke T . Diagnostic value of retrospective PET-MRI fusion in head-and-neck cancer. BMC Cancer. 2014; 14:846. PMC: 4252007. DOI: 10.1186/1471-2407-14-846. View